Skip to content

Efficacy and Safety of Photodynamic Therapy for Unresectable Cholangiocarcinoma

Efficacy and Safety of Photodynamic Therapy for Unresectable Cholangiocarcinoma

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02585856
Enrollment
39
Registered
2015-10-23
Start date
2013-02-28
Completion date
2018-08-31
Last updated
2018-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholangiocarcinoma

Keywords

Biliary duct carcinoma, Photodynamic therapy

Brief summary

The aim of this study is to investigate the efficacy of photodynamic therapy (PDT) in increasing the survival time, decreasing cholestasis and improving health-related quality of life (HRQoL) by comparing PDT puls stents versus stents alone in patients with unresectable cholangiocarcinoma,and to assess the safety of PDT by observing the complications after the procedure.

Detailed description

Cholangiocarcinoma (CCA) is difficult to diagnose due to its anatomic location, clinical course, and lack of definitive diagnostic criteria. It is often clinically silent with symptoms developing only in advanced disease. Surgical resection is the recommended curative intervention with only a minority of patients (10-20%) having potentially resectable tumors at time of diagnosis. Endoscopic palliative therapy in CCA entails the relief of obstructive jaundice through transpapillary or percutaneous insertion of plastic or metal biliary stents. Although biliary decompression provides relief of cholangitis and improvement in quality of life, it does not improve survival. Photodynamic therapy (PDT) in conjunction with biliary stenting may improve bile duct patency by local obliteration of malignant tissue through the cytotoxic effects of reactive oxygen species. Several studies suggest PDT plus biliary stent placement may prolong survival (range of 360-630 days), reduce cholangitis, and improve the quality of life of patients with advanced disease. The aim of this study is to determine the effectiveness and safety of PDT with biliary stenting compared to biliary stenting alone in the palliative treatment of unresectable CCA in China.

Interventions

DEVICEPDT

Patients with unresectable CCA are performed PDT with ERCP after porfimer sodium (chongqing ray high medical instrument co., LTD,Chongqing, China) i.v. at a dose of 2 mg/kg at 48 h. PDT procedure: for light distribution, flexible cylindrical diffuser probes mounted on 400-mm quartz fibres with an active distal tip length of 2 cm (chongqing ray high medical instrument co., LTD,Chongqing, China) is used. The light source was a diode laser system with a maximum power output of 2 Wand a wavelength of 633.3 nm. The power emitted by the diffuser tip was calibrated to 400 mW/cm before PDT was administered using an integrating sphere power meter. The mean irradiation time was 452 s (range: 400-600 s), using a power density of 300-400 mW/cm and an energy dose of 180-200 J/cm (of diffuser length).

DEVICEstent

Patients with unresectable CCA are performed with ERCP, one or several plastic biliary stents (Boston Scientific Corporation, MA,USA) are inserted to ensure adequate decompression and bile drainage.

Sponsors

First People's Hospital of Hangzhou
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Obtention of a written informed consent. * Patient over 18. * Patient with histologically proved cholangiocarcinoma ; histologic diagnosis must be proved by biliary brushing, bile cytology, endobiliary biopsy under Spyglass, or by EUS-FNA. * Patient with Karnofsky score ≥ 50 % * Patient capable of fill in the quality of life questionnaire

Exclusion criteria

* No written informed consent. * Patients under or already treated by radiotherapy or chemotherapy treatment for cholangiocarcinoma. * Patients with porphyria or hypersensibility to porphyrins. * Pregnant, parturient or breastfeeding women. * Patient under 18.

Design outcomes

Primary

MeasureTime frame
survival timetwo years

Secondary

MeasureTime frameDescription
clinical success ratestwo yearsThe proportion of patients whose bilirubin decreased obviously after procedure
Karnosky performance status scoretwo years
complicationstwo yearsNumber of patients with complications,type, frequency and intensity of complications between this two group will be compared

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026